Insider Buying: CapsoVision (NASDAQ:CV) Major Shareholder Buys 878,734 Shares

Posted by Brian Himes on Sep 18th, 2026

CapsoVision, Inc. (NASDAQ:CV – Get Free Report) major shareholder Ching Hang Shen bought 878,734 shares of the company’s stock in a transaction that occurred on Tuesday, September 15th. The shares were bought at an average cost of $5.69 per share, for a total transaction of $4,999,996.46. Following the transaction, the insider directly owned 2,926,655 shares of the company’s stock, valued at $16,652,666.95. This trade represents a 42.91% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

CapsoVision Price Performance

Shares of CV traded up $0.37 on Friday, reaching $6.70. 1,614,307 shares of the stock traded hands, compared to its average volume of 250,210. The firm has a market cap of $335.33 million, a price-to-earnings ratio of -14.26 and a beta of -2.47. The stock’s 50-day moving average price is $6.40 and its 200-day moving average price is $6.52. CapsoVision, Inc. has a 12 month low of $4.34 and a 12 month high of $15.37.

CapsoVision (NASDAQ:CV – Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.15) earnings per share (EPS) for the quarter. CapsoVision had a negative return on equity of 177.85% and a negative net margin of 214.74%.The business had revenue of $3.64 million during the quarter. As a group, equities research analysts forecast that CapsoVision, Inc. will post -0.56 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on CV shares. Weiss Ratings reissued a “sell (d-)” rating on shares of CapsoVision in a report on Monday, June 29th. Roth Capital began coverage on shares of CapsoVision in a research note on Friday, August 28th. They set a “buy” rating and a $9.00 price target for the company. Benchmark restated a “speculative buy” rating on shares of CapsoVision in a report on Friday, August 14th. Finally, Zacks Research raised CapsoVision to a “hold” rating in a research note on Monday, August 31st. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, CapsoVision presently has an average rating of “Hold” and a consensus price target of $9.50.

Check Out Our Latest Report on CV

Hedge Funds Weigh In On CapsoVision

Several institutional investors and hedge funds have recently made changes to their positions in the company. Connective Capital Management LLC acquired a new stake in CapsoVision during the 2nd quarter worth $76,000. Bank of America Corp DE acquired a new position in CapsoVision in the second quarter valued at about $193,000. Legal & General Group Plc acquired a new position in CapsoVision in the second quarter valued at about $26,000. BlackRock Inc. bought a new stake in shares of CapsoVision in the second quarter worth about $14,372,000. Finally, Deutsche Bank AG bought a new stake in shares of CapsoVision in the second quarter worth about $263,000.

CapsoVision Company Profile

(Get Free Report)

CapsoVision, Inc is a medical technology company focused on developing and commercializing capsule endoscopy systems for gastrointestinal (GI) diagnostics. Its products are designed to help physicians examine the digestive tract, particularly the small intestine, using an ingestible capsule rather than a conventional endoscopic procedure.

The company’s principal product is CapsoCam Plus, an ingestible capsule endoscope that captures panoramic images as it travels through the gastrointestinal tract.